ESTEVE-JARAMILLO, Alejandra
y
LOPEZ-COLLADA, Vesta L Richardson. Hacia la erradicación de la poliomielitis: logros y retos en México. Salud pública Méx [online].
2012,
vol.54, n.5, pp. 537-543.
ISSN 0036-3634.
|
|
2. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Geneva: World Health Organization, 1988; resolution WHA41.28. [ Links ] 3. Robertson SE, Chan C, Kim-Farley R, Ward N. Worldwide status of poliomyelitis in 1986, 1987 and 1988, and plans for its global eradication by the year 2000.World Health Stat Q 1990;43:80-90. [ Links ] 4. Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--the Americas, 1994. MMWR Morb Mortal Wkly Rep 1994; 43:720-722. [ Links ] 5. Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--Western Pacific Region, October 2000. MMWR Morb Mortal Wkly Rep 2001; 50:1-3. [ Links ] 6. Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--European Region, June 2002. MMWR Morb Mortal Wkly Rep 2002;51:572-574. [ Links ] 7. World Health Organization. Country Office Tajikistan; WHO Regional Office for Europe; European Centre for Disease Prevention and Control. Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe? Euro Surveill 2010;15. [ Links ] 8. Centers for Disease Control and Prevention (CDC). Outbreaks fo-llowing wild poliovirus importations. Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1393-1399. [ Links ] 9. Smith J, Leke R, Adams A, Tangermann RH. Certification of polio eradication: process and lessons learned. Bull World Health Organ 2004; 82:24-30. [ Links ] 11. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 1957;164:1216-1223. [ Links ] 10. Sabin AB. Status of field trials with an orally administered, live attenuated poliovirus vaccine. J Am Med Assoc 1959;171:863-868. [ Links ] 12. Ramos-Alvarez M, Bustamante ME, Alvarez Alba R. The use of the Salk vaccine, in the polio live virus, in Mexico: Study Results. Bol Oficina Sanit Panam 1961; 50:305-322. [ Links ] 13. Consejo Nacional de Vacunación. Manual de vacunación 2008-2009. México, D.F: CONAVA 2008: 405. [ Links ] 14. Instituto Nacional de Salud Pública. Encuesta Nacional de Cobertura de Vacunación. Cuernavaca, Morelos: INSP, 2010: 54. [ Links ] 15. Díaz-Ortega J, Valdespino JL, Zárate ML, Camacho L. Seroconversión a la vacuna Sabin trivalente en niños menores de 4 años de edad. Bol Hosp Inf Mex 1989; 46:517-520. [ Links ] 16. Ruiz-Gómez J, Tapia-Conyer R, Salvatierra B, et al. Seroepidemiología de la poliomielitis en México. Salud Publica Mex 1992; 34:168-176. [ Links ] 17. Ruiz-Gómez J, Valdespino JL, Olaiz-Fernández G, Arias-Toledo E, Se-púlveda J. Seroprevalencia de anticuerpos contra el poliovirus 1 en niños mexicanos. Salud Publica Mex 2007;49:S361-S369. [ Links ] 18. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol 2003;13(5):277-291. [ Links ] 19. Aylward RB, Sutter RW, Heymann DL. Policy: OPV cessation - the final step to a 'polio-free' world. Science 2005; 310: 625-626. [ Links ] 20. Global Polio Eradication Initiative. Framework for National Policy Makers in OPV-Using Countries [internet]. Ginebra, (Suiza): World Health Organization; 2008 Dec [consultado 30 de noviembre de 2011] 11p. Disponible en: http://www.polioeradication.org/content/publications/OPVCessationFrameworkEnglish.pdf [ Links ] 21. Albrecht RM. Poliomyelitis from a vaccinee. Lancet 1968; 1:1371. [ Links ] 22. Nkowane BM, Wassilak SGF, Orenstein WA, et al. Vaccine associated paralytic poliomyelitis, United States: 1961-72. JAMA 1987; 257: 1335-1340. [ Links ] 23. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 1988; 66:739-746. [ Links ] 24. Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizou H, Nathan-son N et al. Circulating vaccine-derivated polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16-23. [ Links ] 25. CDC. Outbreak of poliomyelitis - Dominican Republic and Haiti, 2000. MMWR Morb Mortal Wkly Rep 2000;49:1094-1103. [ Links ] 26. Zurbriggen S, Tobler K, Abril C, Diedrich S, Ackermann M, Pallansch MA, et al. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl Environ Microbiol 2008; 74:5608-5614. [ Links ] 27. Troy SB, Ferreyra-Reyes L, Huang C, Mahmud N, Lee YJ, Canizales-Quintero S. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a mexican national immunization day. J Clin Microbiol 2011;49:1777-1783. [ Links ] 28. Duintjer-Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol 2005; 162:358-372. [ Links ] 29. Salas-Peraza D, Avila-Agüero ML, Morice-Trejos A. Switching from OPV to IPV: are we behind the schedule in Latin America? Expert Rev Vaccines 2010;9:475-483. [ Links ] 30. Sutter R, Prevots DR, Cochi SL. Introduction of inactivated poliovirus vaccine into oral polio vaccine-using countries. Wkly Epidemiol. Rec 2003; 78: 241-252. [ Links ] 31. Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011;10:635-644. [ Links ] 32. World Health Organization. Global Polio Erradication Initiative [Internet] Ginebra (Suiza) 1996- [Consultado 30 de marzo 2012]. Disponible en: ttp://apps.who.int/immunization_monitoring/en/diseases/poliomyelitis/ case_count.cfm [ Links ] 33. Arya SC, Agarwal N. Global polio laboratory network: future pursuit and commitments. J Clin Virol 2007;38:362-363. [ Links ] 34. Completion of national laboratory inventories for wild poliovirus containment:WHO Region of the Americas, March 2010. Wkly Epidemiol Rec 2010; 85:329-333. [ Links ] |
